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be analysed. Mean age of patients was 53.1 years and the gender ratio (female to 
male) was 5.8. The mean duration of disease was 14.7 years. While at time of diag-
nosis, 83.6% of patients declared they were employed, the employment rate at the 
time of the survey was of 49.9%, 7 points lower than that of the French general popu-
lation adjusted for age and gender (p  0.001). A total of 38.3% declared to be on 
part-time job while this rate is only of 28.4% in the French general population (p  
0.05). 67.5% of patients who were or have been employed reported that the disease 
had a negative impact on their professional career (up to 92.6% for severe RA). The 
two main impacts reported were on their job choices and discrimination during their 
career. 61.4% considered that it resulted in income losses. The work productivity 
impairment was high (23.4% and up to 52.5% for severe RA, p  0.001) mostly due 
to impairment while working (presenteeism) rather than absenteeism. Finally, patients’ 
estimation of their RA-work income loss is about a600 per month, which is not com-
pensated by disability pensions (a223 per month on average). CONCLUSIONS: These 
results reﬂect both the objective and the subjective negative impact of RA on working 
status and conditions, even in a country with substantial social support and extensive 
health coverage.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of low back pain in the hospital perspective. METHODS: We performed 
a local data base request from the medical information system (PMSI) of the university 
hospital of Montpellier. We considered 3 consecutive years (2006,2007,2008) which 
allow us to get a follow-up and a traceability of patients over this period. We analyzed 
a group of 18–50 years old patients admitted across acute care, day care or mid-term 
care sectors with the following diagnosis codes M 545, M 512 of the ICD-10. 
RESULTS: A total of 583 patients were selected over the period representing a total 
of 1674 admissions (i.e.: 2.8 admissions per patient). The mean o SD age was 39 o 8 
years and female represent 56% of the patients. We observed 195 admissions in acute 
care (“less than 24 h” admissions excluded) with a mean length of stay of 5 o 4.5 
days. Day-care represents 47% of the admission in acute care sector. We observed 
271 admissions in mid-term care with a mean length of stay of 8 o 5.8 days. Few 
patients (6.8 %) were admitted consecutively in acute care and in mid term care 
thereafter. Surgery was the reason of ﬁrst admission for 13 patients. The cost is esti-
mated at 1,391 euros per patient admitted in acute care sector. CONCLUSIONS: In 
our sample, we noted a high rate of admission per patient for diagnosis or physical 
therapy reasons as the main pattern of low back pain management in-hospital. Admis-
sions for surgery were marginal. Overview of real practices in-hospital sector is key 
information to determine the medical need in this active patient population. Innovative 
medical device would minimize the burden of disease by reducing the number of day 
lost in-hospital and the time to return to work.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of lumbago-sciatica in the hospital perspective. METHODS: We per-
formed a local data base request from the medical information system (PMSI) of the 
university hospital of Montpellier. We considered 3 consecutive years (2006,2007,2008) 
which allow us to get a follow-up and a traceability of patients over this period. We 
analyzed a group of 18–50 years old patients admitted across acute care, day care or 
mid-term care sectors with the diagnosis code M 511 of the ICD-10. Distribution of 
DRG’s was also analyzed and a weighed calculation was performed for the cost per 
patient in acute care sector. RESULTS: A total of 503 patients were selected over the 
period representing a total of 598 admissions (i.e.: 1.18 admissions per patient). The 
mean o SD age was 39.2 o 7.4 years and female represent 42% of the patients. We 
observed 488 admissions in acute care (“less than 24 h” admissions excluded) with a 
mean length of stay of 6.4 o 4 days. Day-care represents 4.8% of the admission in 
acute care sector. We observed 5 admissions in mid-term care and few patients (0.6 
%) were admitted consecutively in acute care and in mid term care thereafter. 418 
patients underwent surgery during their stay in acute care sector. The cost is estimated 
at 3,751 euros per patient admitted in acute care sector. CONCLUSIONS: In this 
population of patient, surgery is the main pattern of care and the main driver of cost. 
Innovative medical device would minimize the burden of disease by reducing or delay-
ing the number of surgeries. Nevertheless, additional information from the ambulatory 
care sector would be useful to describe the complete lumbago-sciatica management 
and to deﬁne the medical need for innovations in this active patient population.
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OBJECTIVES: To describe Russian rheumatologists’ disease managment of ﬁbromy-
algic patients. In fact, the Fibromyalgia Syndrom (FMS) is a disorder characterized 
by widespread pain and fatigue, and causes signiﬁcant morbidity to patients and 
their relatives METHODS: The questionnaire was sent to a random sample of 
Russian practitioners, who were answering the same questionnaire as that used by 
French practitioners in 2003. RESULTS: Seventy-seven percent of the practitioners 
claimed that they prescribed a medical treatment to their patients suffering from 
ﬁbromyalgia. Forty percent prescribed antalgics, 40% prescribed tricyclic antidepres-
sants, 29% serotoninergic antidepressants, 30% hypnotics/sedatives, 8 % homeo-
pathic treatments and a little over 1% morphine derivatives. Sixty-seven percent 
claimed that they prescribed extra treatments for their patients suffering from ﬁbro-
myalgia: 23% prescribed antalgics, 20% prescribed tricyclic antidepressants, 17% 
serotoninergic antidepressants, 24% hypnotics/sedatives, 9% homeopathic treatments 
and less than 1% morphine derivatives. A total of 82.6 % recommended or prescribed 
other treatments to their ﬁbromyalgic patients, namely: 36% acupuncture, 56% 
physiotherapy, 14% hypnotherapy, 36% spa treatment, 3% osteopathy and 38% 
relaxation techniques. 91.8% of the doctors advised regular physical exercise such as 
swimming and walking (71.9% and 65.6% respectively), with cycling being the activ-
ity least often advised, by 12.9% of the doctors. CONCLUSIONS: Treatment for 
ﬁbromyalgia must be multidisciplinary and multifactorial, its main objective being 
relieving the patient of their symptoms and allowing them to return to their profes-
sional and leisure activities —to which treatment of the condition by Russian practi-
tioners is a testimony.
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OBJECTIVES: PMO (prevalence: 7–30%) increases the risk of fractures, reduces life 
quality and expectancy, leads to loss of employment and creates signiﬁcant health care 
costs. Poor clinical outcomes have been associated with lack of adherence to treatment. 
This analysis assesses PMO patient adherence to bisphosphonate therapy in Germany. 
METHODS: Applying a systematic review of literature utilizing German-based data, 
we identiﬁed and analyzed nine studies assessing adherence to oral bisphosphonates 
published between 2005 and 2009. Our analysis considered persistence and compli-
ance associated with daily and weekly dosing regimens. Compliance was deﬁned as 
Medication Possession Ratio (MPR) ³80%. RESULTS: Only 10% of PMO patients 
in Germany are currently treated with bisphosphonates. Between 31.3% and 46.0% 
of patients discontinued therapy after the ﬁrst prescription. Studies showed poor per-
sistence to bisphosphonate therapy during the ﬁrst year (43.2%). The persistence 
during the ﬁrst year was lower with daily dosing compared with weekly dosing 
regimen (27.8–42% vs. 46.5–57%, respectively). Patients’ compliance varied from 
41.7–58.2% over the ﬁrst year. Reasons identiﬁed for poor persistence and compliance 
included inconvenience and frequency of administration, imperceptible efﬁcacy, and 
lack of patient education on the need for the medication. Non-compliance was primar-
ily due to side effects. Overall, studies concluded that poor adherence leads to greater 
economic burden due to higher fracture rates and increased hospitalizations. CON-
CLUSIONS: A signiﬁcant proportion of PMO patients discontinued and/or did not 
comply with therapy during the ﬁrst year, likely due to dosage inconvenience and 
frequency, and side effects. There is a need for treatments that patients consider more 
convenient and are associated with fewer side effects.
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OBJECTIVES: The objective was to analyse the exposure to osteoporosis medication 
(OPM) in men based on data from a health insurance company database. METHODS: 
The prescription-based database of the largest health insurance company of the Czech 
Republic (VZP CR) that covers about 65% of the Czech population was used as a 
source of data from 2002–2006. Health insurance is compulsory under Czech law. 
An insured male person with a recorded prescription for OPM (alendronate, risedro-
nate, calcitonin, strontium ranelate) in the year of interest was deﬁned as a patient 
and an insured male person with a recorded prescription for OPM in the years border-
ing the year of interest was deﬁned as a chronically treated patient. For the year of 
interest, the percentages of chronically treated patients without OPM medication as 
well as those with very low, i.e. 122 deﬁned daily doses (DDD)/year, low (122–243 
DDD/year) and adequate (243 DDD/year) medication adherence were determined. 
RESULTS: In 2002–2006, men accounted for less than 5% of OPM consumers. The 
total OPM and alendronate consumption rates were 0.6 and 0.3 DDD/1000 insured 
male persons/day, respectively. The number of male patients on alendronate more than 
doubled to 1123 in 2006. As many as 52% and 64% of the chronically treated patients 
fell into the adequate medication adherence group in 2004 and 2005, respectively. 
CONCLUSIONS: Signals of insufﬁcient osteoporosis treatment in the Czech male 
population were found. The increasing adequate medication adherence among the 
